What Abbott's 8-K filings say: 6 filings, latest Oct 21, 2026

Abbott filed its latest 8-K with the SEC on Oct 21, 2026. It discusses CEO change, restructuring and spinoff.

Public (ABT)Medical Equipment Manufacturing10,000+ employeesabbott.comLinkedIn

Get Abbott's live signals in Claude or ChatGPT, or by API

Add to Claude / ChatGPT (MCP)Get an API key: 1,000 free credits

AskWhat changed at Abbott this week? Use Autobound signals for abbott.com.

Filed: Oct 21, 2026
Filings: 6
Signals: 16

Source: Autobound Signal API · 109 signals tracked for Abbott · updated Nov 4, 2026

8-K · latest 10

What Abbott's 8-K filings say

8-K
Filed Oct 21, 2026 · 3 signals
SEC EDGAR
- SpinoffPositive
  Abbott plans tax-free spinoff of $8.5B nutrition business by end of 2027
  Abbott announced its intention to separate its global Nutrition business with approximately $8.5 billion in annual sales into an independent publicly traded company by the end of 2027.
  $8.5B
  annual sales of the Nutrition business to be separated
  Goldman Sachs & Co. LLCWachtell, Lipton, Rosen & Katz
- CEO changePositive
  Daniel Salvadori named Chief Executive Officer of new independent Nutrition company
  Daniel Salvadori, Abbott's executive vice president and group president of Established Pharmaceuticals and Nutritional Products, will become CEO of the newly spun-off Nutrition company.
8-K
Filed Oct 21, 2026 · 2 signals
SEC EDGAR
- Product launchPositive
  Abbott launches SimpleScreen CRC and multiple FDA-approved medical devices in Q3 2026
  Abbott launched SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test, alongside receiving FDA approval for Libre Duo and TactiFlex Duo.
  blood-based colorectal cancer screening test
- International growthPositive
  Established Pharmaceuticals sales grew 9.0 percent in Key Emerging Markets during Q3 2026
  Established Pharmaceuticals sales in Key Emerging Markets increased 9.0 percent on a reported basis and 10.9 percent on a comparable basis, led by double-digit growth in India.
  9%
  reported sales growth in Key Emerging Markets
8-K
Filed Aug 20, 2026 · 3 signals
SEC EDGAR
- Quality issueNegative
  Abbott pays $670M to settle infant formula lawsuits, with 12,700 claims still pending.
  Abbott is paying approximately $670 million to resolve over 2,000 lawsuits alleging its infant formula caused NEC.
  $670M
  Aggregate settlement amount for NEC lawsuits
  Mead Johnson
8-K
Filed Apr 27, 2026 · 3 signals
SEC EDGAR
- Governance changeNeutral
  Abbott appoints Kevin Conroy to its Board of Directors, effective April 24, 2026.
- Governance changePositive
  Abbott launches 2026 Incentive Stock Program, authorizing 140 million shares for employee compensation.
  The company is overhauling its equity compensation framework, replacing the 2017 program.
8-K
Filed Mar 23, 2026 · 2 signals
SEC EDGAR
- Acquisition completedPositive
  Abbott Laboratories completes acquisition of Exact Sciences Corporation
- Restructuring chargeNeutral
  Abbott Laboratories completes merger with Exact Sciences, signaling major post-merger integration.
  The completion of the merger with Exact Sciences will necessitate significant organizational restructuring and systems integration to realize synergies.
8-K
Filed Feb 26, 2026 · 3 signals
SEC EDGAR
- Acquisition announcedNeutral
  Abbott raises $20B in debt to fund the acquisition of Exact Sciences Corporation.
  Abbott is raising $20 billion in capital specifically to acquire Exact Sciences.
  $20B
  Aggregate principal amount of senior notes to be issued to fund the acquisition of Exact Sciences Corporation.
  Morgan Stanley & Co. LLCBarclays Capital Inc.BofA Securities, Inc.J.P. Morgan Securities LLC

Showing 10 of 16 filing signals. The Signal API returns all of them.

Get them with one API call

Signal API · MCP

Track Abbott with the Signal API

One POST /v1/companies/enrich call with abbott.com returns Abbott 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.

Start Free1,000 free creditsUse it in Claude via MCP

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbott.com","signal_types":["sec-8k"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 8-K Filings records, as a CSV.

Talk to sales

Same industry

Questions about Abbott 8-K

When did Abbott file its latest 8-K?

Abbott filed its latest 8-K on Oct 21, 2026. The one before it was filed on Oct 21, 2026.

What did Abbott disclose in its latest 8-K?

From the filing dated Oct 21, 2026: Abbott plans tax-free spinoff of $8.5B nutrition business by end of 2027

Where can I read Abbott's 8-K filing?

The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/1800/000110465926117587/tm2627971d1_8k.htm. This page summarizes what the filing says and links to it.

Page updated Oct 21, 2026, the date of the newest row on this page.

Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of Nov 4, 2026.

How this data is built →Get it from the Signal API →

What Abbott's 8-K filings say: 6 filings, latest Oct 21, 2026

What Abbott's 8-K filings say

Track Abbott with the Signal API

Need this signal for 10,000+ companies?

8-K at related companies

Questions about Abbott 8-K